Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in antifungal strategy.

Anjali Shetty1, Rosemary A Barnes

  • 1Department of Medical Microbiology, University Hospital of Wales, Heath Park, Cardiff, UK. anjalishettyuk@yahoo.co.uk

Expert Review of Anti-Infective Therapy
|October 16, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A study on the antifungal susceptibility pattern of Aspergillus species.

Indian journal of medical microbiology·2026
Same author

Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry: A breakthrough in rapid and precise mold identification.

Current medical mycology·2026
Same author

Evaluation of the rapid lateral flow assay (LFA) for detection of five major carbapenemase enzyme families in genotypically characterised bacterial isolates.

The Indian journal of medical research·2025
Same author

The Molecular Diagnosis of Invasive Fungal Diseases with a Focus on PCR.

Diagnostics (Basel, Switzerland)·2025
Same author

Correlation of Trace detection in Gene Xpert MTB/RIF ultra with MGIT TB culture in a high TB-endemic Country.

Tuberculosis (Edinburgh, Scotland)·2025
Same author

The diagnosis of mucormycosis by PCR in patients at risk: a systematic review and meta-analysis.

EClinicalMedicine·2025
Same journal

<i>Pneumocystis</i> pneumonia in non-HIV immunocompromised patients in 2026: evolving therapeutic standards.

Expert review of anti-infective therapy·2026
Same journal

Asymptomatic is not silent: proposal of HTLV-1-associated multiple inflammatory disease as an early neuroinflammatory state.

Expert review of anti-infective therapy·2026
Same journal

The endocarditis team: a review.

Expert review of anti-infective therapy·2026
Same journal

Synergistic antifungal effects and potential mode of action of crisaborole combined with azoles against drug-resistant <i>Candida albicans</i>.

Expert review of anti-infective therapy·2026
Same journal

Anti-infective therapy and novel treatment options for coccidioidomycosis.

Expert review of anti-infective therapy·2026
Same journal

Intensivists' practices and perceptions regarding β-lactam prescribing and monitoring in intensive care units: a cross-sectional survey.

Expert review of anti-infective therapy·2026
See all related articles

New antifungal drugs offer improved safety and efficacy for invasive fungal infections in immunocompromised patients. Advances in diagnostics enable more rational use of these treatments and potential immunomodulatory strategies.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Invasive fungal infections (IFIs) pose a significant threat, causing severe morbidity and mortality in immunocompromised individuals.
  • Development of novel antifungal agents, including triazoles and echinocandins, is crucial due to the rising incidence of IFIs.
  • Inadequate diagnosis has historically limited the evaluation of antifungal therapies, resulting in a weak evidence base for prophylactic and empirical strategies.

Purpose of the Study:

  • To review recent advances in the diagnosis and treatment of invasive fungal infections.
  • To discuss the role of newer antifungal agents and potential adjunctive therapies.

Main Methods:

  • Literature review of recent advances in antifungal diagnostics and therapeutics.

Related Experiment Videos

  • Analysis of clinical trial data and evidence supporting current treatment strategies.

    • Main Results:

    • Recent diagnostic improvements enhance the rational application of antifungal treatments.
    • Newer antifungal agents demonstrate proven efficacy and improved safety profiles.
    • Understanding of host immune responses opens avenues for novel adjunctive and immunomodulatory therapies.

    Conclusions:

    • Improved diagnostic criteria are essential for effective management of invasive fungal infections.
    • Newer antifungal agents represent a significant advancement in treating immunocompromised patients.
    • Future strategies may involve combining antifungals with immunomodulatory approaches for enhanced patient outcomes.